“`html
CERN-Led PRISMAP Program Fuels Breakthroughs in Cancer Research with Novel Radionuclides
Table of Contents
A European initiative coordinated by CERN has delivered a notable boost to cancer research, supplying 159 batches of crucial radioactive materials – known as radionuclides – to laboratories across 19 countries over the past five years.The program, known as PRISMAP, is designed to overcome a key hurdle in the growth of new cancer treatments: access to these specialized materials.
The Rise of ‘Theranostics’ and the need for Radionuclides
nuclear medicine utilizes radionuclides for both imaging and therapeutic applications. These unstable nuclei emit radiation that can selectively damage or destroy cancer cells. Over the last decade, a revolutionary approach called “theranostics” has gained prominence, combining diagnostic imaging with targeted therapy to personalize cancer treatment for each patient. While two radiopharmaceuticals have already been approved for treating neuroendocrine and prostate cancers,the development pipeline remains robust,yet hampered by limited access to the necessary radionuclides during early-stage research.
PRISMAP: Bridging the Gap in Radionuclide Access
The primary goal of PRISMAP – the European medical radionuclides programme – was to address this critical need by providing access to new, high-purity radionuclides, thereby accelerating research into targeted medical treatments. “By connecting eight radionuclide production facilities and five biomedical research centres across Europe, the project has undoubtedly stimulated research into cancer treatment,” explained a senior official associated with the program.
Over the past five years, PRISMAP has directly supported 47 medical research projects. Beyond simply supplying the materials, the program also offered researchers the prospect to conduct projects at its five specialized biomedical facilities, providing access to equipment and authorizations that might otherwise be unavailable.
Alpha Emitters and the future of cancer Treatment
A notably promising area of focus for PRISMAP has been the supply of alpha-emitting radionuclides. These particles – essentially helium ions comprised of two protons and two neutrons – offer a unique advantage in cancer therapy. They target cancer cells with greater precision than other forms of radiation, minimizing damage to healthy tissue and proving particularly effective against micro-metastases, a major challenge in oncology.
CERN-MEDICIS, a facility operated by CERN, stands alone as the world’s only dedicated producer of radionuclides by mass separation for biomedical research. This process yields exceptionally pure nuclides. By combining radionuclides produced in traditional cyclotrons and nuclear reactors with CERN-MEDICIS’s mass separation techniques, PRISMAP has delivered truly innovative materials to researchers.
Lead Isotopes and Prostate Cancer Research
One compelling example of PRISMAP’s impact involves the combination of two isotopes of lead. Pb-203, sourced from the ARRONAX nuclear reactor in Nantes, France, was combined with pb-212 from CERN-MEDICIS and delivered to Dresden Hospital for research focused on the diagnosis and treatment of prostate cancer. “The PRISMAP project was instrumental in developing this highly innovative theranostic approach,” a program representative stated. “The initial results recently published are very encouraging.”
Looking Ahead: PRISMAP+ and Continued Innovation
The original PRISMAP project concluded on December 31, 2025. Recognizing the program’s success, a funding request has been submitted for a three-year follow-up project, PRISMAP+, aimed at sustaining and expanding the established network. The continued availability of these critical radionuclides promises to further accelerate breakthroughs in the fight against cancer.
